Ifp Advisors, Inc Vaxart, Inc. Transaction History

Ifp Advisors, Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$2.7 - $5.28 $1,922 - $3,759	712 New	712 $3,000
Q2 2022 Aug 12, 2022	SELL	$2.7 - $5.28 $1,922 - $3,759	-712 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$4.29 - $6.64 $1,081 - $1,673	252 Added 54.78%	712 $3,000
Q4 2021 Jan 12, 2022	BUY	$5.77 - $7.96 $2,654 - $3,661	460 New	460 $3,000
Q3 2021 Oct 06, 2021	SELL	$6.67 - $9.8 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	SELL	$5.06 - $10.78 $5,060 - $10,780	-1,000 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$5.64 - $23.33 $2,820 - $11,665	500 Added 100.0%	1,000 $6,000
Q4 2020 Jan 25, 2021	BUY	$3.5 - $7.98 $1,694 - $3,862	484 Added 3025.0%	500 $3,000
Q3 2020 Oct 29, 2020	BUY	$4.78 - $16.97 $76 - $271	16 New	16 $0
Q2 2020 Aug 05, 2020	BUY	$1.68 - $8.85 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$0.34 - $2.87 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	SELL	$0.28 - $0.39 $45 - $63	-162 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$0.3 - $0.75 $48 - $121	162 New	162 $0
Q1 2019 May 15, 2019	SELL	$1.5 - $2.34 $3 - $4	-2 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$4.95 - $9.02 $9 - $18	2 New	2 $0

108

37.9M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $93.6M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.